novacyt sas - NVYTF

NVYTF

Close Chg Chg %
0.51 -0.03 -5.90%

Open Market

0.48

-0.03 (5.90%)

Volume: 100.00

Last Updated:

Jan 2, 2026, 9:30 AM EDT

Company Overview: novacyt sas - NVYTF

NVYTF Key Data

Open

$0.48

Day Range

0.48 - 0.48

52 Week Range

0.48 - 0.64

Market Cap

$33.90M

Shares Outstanding

70.63M

Public Float

70.48M

Beta

1.66

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

NVYTF Performance

No Data Available

NVYTF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About novacyt sas - NVYTF

Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. It operates through the following segments: Primer Design, IT-IS International, and Corporate. The Primer Design segment focuses on the activities of Primer Design Ltd, which is a designer, manufacturer, and marketer of molecular real-time qPCR testing devices and reagents. The IT-IS International segment is involved in IT-IS International Ltd, a diagnostic instrument development and manufacturing company specializing in the development of PCR devices for the life sciences and food testing industry. The Corporate segment includes group central and corporate costs. The company was founded by Eric Peltier, Gerald Ulrich, and Jean-Pierre Crinelli on July 3, 2006 and is headquartered in Velizy-Villacoublay, France.

NVYTF At a Glance

Novacyt SAS
131 Boulevard Carnot
Le Vésinet, Ile-de-France 78110
Phone 33-1-39-46-51-04 Revenue 25.08M
Industry Medical Specialties Net Income -53,358,886.48
Sector Health Technology 2024 Sales Growth 74.272%
Fiscal Year-end 12 / 2025 Employees N/A
View SEC Filings

NVYTF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.755
Price to Book Ratio 0.734
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.803
Enterprise Value to Sales 0.827
Total Debt to Enterprise Value 0.717

NVYTF Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 3.875
Total Asset Turnover 0.194

NVYTF Liquidity

Current Ratio 6.326
Quick Ratio 5.961
Cash Ratio 4.897

NVYTF Profitability

Gross Margin 125.909
Operating Margin -83.362
Pretax Margin -200.866
Net Margin -212.725
Return on Assets -38.178
Return on Equity -57.775
Return on Total Capital -66.074
Return on Invested Capital -49.349

NVYTF Capital Structure

Total Debt to Total Equity 24.809
Total Debt to Total Capital 19.878
Total Debt to Total Assets 16.817
Long-Term Debt to Equity 22.183
Long-Term Debt to Total Capital 17.774
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Novacyt Sas - NVYTF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
131.73M 25.92M 14.39M 25.08M
Sales Growth
-62.94% -80.33% -44.46% +74.27%
Cost of Goods Sold (COGS) incl D&A
44.47M 21.44M 14.92M (6.50M)
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.76M 2.61M 5.16M 9.40M
Depreciation
- - 3.02M 5.02M
-
Amortization of Intangibles
- - 2.14M 4.38M
-
COGS Growth
-48.24% -51.78% -30.42% -143.56%
Gross Income
87.25M 4.47M (527.05K) 31.58M
Gross Income Growth
-67.63% -94.87% -111.78% +6,092.25%
Gross Profit Margin
+66.24% +17.26% -3.66% +125.91%
2021 2022 2023 2024 5-year trend
SG&A Expense
39.29M 24.45M 21.75M 52.49M
Research & Development
6.62M 6.22M 4.01M 3.54M
Other SG&A
32.67M 18.23M 17.74M 48.96M
SGA Growth
-12.77% -37.77% -11.03% +141.33%
Other Operating Expense
- - - -
-
Unusual Expense
59.00M 9.44M 13.62M 25.33M
EBIT after Unusual Expense
(11.04M) (29.41M) (35.90M) (46.24M)
Non Operating Income/Expense
(2.03M) 5.28M 1.47M (3.13M)
Non-Operating Interest Income
- 959.56K 913.64K 274.73K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
446.97K 565.39K 1.09M 1.01M
Interest Expense Growth
-84.29% +26.49% +92.16% -6.61%
Gross Interest Expense
446.97K 565.39K 1.09M 1.01M
Interest Capitalized
- - - -
-
Pretax Income
(13.52M) (24.70M) (35.51M) (50.38M)
Pretax Income Growth
-106.38% -82.73% -43.77% -41.88%
Pretax Margin
-10.26% -95.31% -246.72% -200.87%
Income Tax
(138.91K) 2.65M (954.66K) (935.36K)
Income Tax - Current - Domestic
(565.25K) 275.92K (294.60K) (175.06K)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
426.34K 2.37M (660.06K) (760.30K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.38M) (27.35M) (34.56M) (49.45M)
Minority Interest Expense
- - - -
-
Net Income
(13.38M) (27.35M) (34.56M) (49.45M)
Net Income Growth
-107.88% -104.40% -26.37% -43.09%
Net Margin Growth
-10.16% -105.52% -240.09% -197.14%
Extraordinaries & Discontinued Operations
- (4.35M) (611.58K) (3.91M)
Discontinued Operations
- (4.35M) (611.58K) (3.91M)
Net Income After Extraordinaries
(13.38M) (31.69M) (35.17M) (53.36M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.38M) (31.69M) (35.17M) (53.36M)
EPS (Basic)
-0.1894 -0.4487 -0.498 -0.7555
EPS (Basic) Growth
-107.61% -136.91% -10.99% -51.71%
Basic Shares Outstanding
70.63M 70.63M 70.63M 70.63M
EPS (Diluted)
-0.1894 -0.4487 -0.498 -0.7555
EPS (Diluted) Growth
-107.61% -136.91% -10.99% -51.71%
Diluted Shares Outstanding
70.63M 70.63M 70.63M 70.63M
EBITDA
50.72M (17.37M) (17.11M) (11.51M)
EBITDA Growth
-77.57% -134.25% +1.48% +32.76%
EBITDA Margin
+38.51% -67.02% -118.90% -45.88%

Novacyt Sas in the News